Difference between revisions of "Hepatoblastoma"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "!style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Efficacy" to "!style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Comparative Efficacy") |
||
| Line 29: | Line 29: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
| − | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | + | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | |[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | ||
| Line 54: | Line 54: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
| − | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | + | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Comparative Efficacy]] |
|- | |- | ||
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2665 Ortega et al. 2000] | |[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2665 Ortega et al. 2000] | ||
Revision as of 03:14, 10 May 2019
| Section editor | |
|---|---|
 |
Wayne H. Liang, MD, MS UAB Birmingham, AL  WayneLiangMD
|
7 regimens on this page
7 variants on this page
|
All lines of therapy
Cisplatin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Perilongo et al. 2009 (SIOPEL 3) | Phase III (E) | Cisplatin & Doxorubicin | Non-inferior complete resection rate |
Chemotherapy
References
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed
Cisplatin & Doxorubicin
| back to top |
PLADO: PLAtinol (Cisplatin) & DOxorubicin
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Ortega et al. 2000 | Phase III (E) | Cisplatin, 5-FU, Vincristine | Seems not superior |
| Perilongo et al. 2009 (SIOPEL 3) | Phase III (C) | Cisplatin | Non-inferior complete resection rate |
Chemotherapy
References
- Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. link to original article PubMed
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed